Unbranded advertising of prescription medicines to the public by pharmaceutical companies
Referencias
Additional references
‘t Jong GW, Stricker B, Sturkenboom M. Marketing in the lay media and prescriptions of terbinafine in primary care: Dutch cohort study. BMJ 2004;328(7445):931.
Association Internationale de la Mutualité, International Society of Drug Bulletins, Health Action International, Medicines in Europe Forum. Second open letter to interested parties. AIM, ISDB, HAI Europe, MiEF 14 June 2007. [haieurope.org/wp‐content/uploads/2012/01/14‐June‐2007‐2nd‐Open‐Joint‐Open‐Letter‐EU‐Commissioners.pdf]
Avery RJ, Kenkel D, Lillard DR, Mathios A, Wang H. Health disparities and direct‐to‐consumer advertising of pharmaceutical products. In: Helmchen L, Kaestner R, Lo Sasso A editor(s). Beyond Health Insurance: Public Policy to Improve Health. Advances in Health Economics and Health Services Research. Vol. 19, Emerald Insight, 2008:71‐94.
Bala MM, Strzeszynski L, Topor‐Madry R, Cahill K. Mass media interventions for smoking cessation in adults. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD004704.pub3]
Basara LR. The impact of a direct‐to‐consumer prescription medication advertising campaign on new prescription volume. Drug Information Journal 1996;30(3):715‐29.
Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the utilization of health care services. Journal of Family Practice 2000;49(2):147–52.
Bond CM, Orru MP, Leder JM, Bouvy M. The over‐the‐counter pharmaceutical market. In: Mossialos E, Mrazek M, Walley T editor(s). Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality. Berskshire: Open University Press, 2004.
Brinn MP, Carson KV, Esterman AJ, Chang AB, Smith BJ. Mass media interventions for preventing smoking in young people. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD001006.pub2]
Cassels A, Hughes MA, Cole C, Mintzes B, Lexchin J, McCormack JP. Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. Canadian Medical Association Journal 2003;168(9):1133‐7.
Castleberry SB, Bayuk K, O’Brien AM. We’ve got a cure for you! Disease awareness campaigns. Journal of Business Case Studies 2008;4(2):31‐7.
Cochrane Consumers, Communication. Standard protocol text and additional guidance for review authors. cccrg.cochrane.org2014.
Chan RJ, Webster J, Marquart L. Information interventions for orienting patients and their carers to cancer care facilities. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD008273.pub2]
Donohue JM, Cevasco M, Rosenthal MB. A decade of direct‐to‐consumer advertising of prescription drugs. New England Journal of Medicine 2007;357(7):673‐81. [DOI: 10.1056/NEJMsa070502]
Cochrane Effective Practice, Organisation of Care (EPOC). What study designs should be included in an EPOC review?. EPOC Resources for Review Authors. Oslo: Norwegian Knowledge Centre for the Health Services, 2013.
Cochrane Effective Practice, Organisation of Care (EPOC). Interrupted time series (ITS) analyses. EPOC Resources for Review Authors. Oslo: Norwegian Knowledge Centre for the Health Services, 2013.
Cochrane Effective Practice, Organisation of Care (EPOC). Suggested risk of bias criteria for EPOC reviews. EPOC Resources for Review Authors. Oslo: Norwegian Knowledge Centre for the Health Services, 2015.
Cochrane Effective Practice, Organisation of Care. How to prepare a risk of bias table for reviews that include more than one study design. EPOC Resources for Review Authors. Oslo: Norwegian Knowledge Centre for the Health Services, 2015.
European Commission. Proposal for a Directive of the European Parliament and of the Council amending, as regards information to the general public on medicinal products subject to medical prescription, Directive 2001/83/EC on the Community code relating to medicinal products for human use. European CommissionDecember 2008.
EGGSI Coordinating Team. Crepaldi C, Lodovici MS, Corsi M. Access to healthcare and long‐term care, equal for women and men?. Expert Group on Gender Equality and Social Inclusion, Health and Long‐Term Care Issues (EGGSI), European Commission2009; Vol. Final Synthesis Report.
European Commission. The state of men's health in Europe. Directorate‐General for Health and Consumers2011; Vol. Report. [DOI: 10.2772/60721]
European Parliament. Disease mongering (Pseudo‐disease promotion). DG Internal Policies2012; Vol. IP/A/ENVI/NT/2012‐20. PE 492.462.
European Parliament and Council. Directive 2004/27/EC of the European Parliament and the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. EU Official Journal2004; Vol. 86, issue 2.
Fugh‐Berman A, Melnick D. Off‐label promotion, on‐target sales. PLoS Medicine 2008;5(10):e210.
Gagnon MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine 2008;5(1):e1. [DOI: 10.1371/journal.pmed.0050001]
Gibson S. Regulating direct‐to‐consumer advertising of prescription drugs in the digital age. Laws 2014;3(3):410‐38.
Gilbody S, Wilson P, Watt I. Benefits and harms of direct to consumer advertising: a systematic review. Quality Safety in Health Care 2005;14(4):246‐50.
Grilli R, Ramsay C, Minozzi S. Mass media interventions: effects on health services utilisation. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD000389]
Haimowitz IJ. Healthcare Relationship Marketing: Strategy, Design and Measurement. Farnham (UK): Gower Publishing Limited, 2011.
Hall D, Jones C. Australian consumer responses to DTCA and other pharmaceutical company sponsored advertisements. Australian and New Zealand Journal of Public Health 2008;32(5):471‐8.
Hall D, Jones S, Iverson D. Disease awareness advertising: women's intentions following exposure. Australian Family Physician 2011;40(3):143‐7.
Handlin A. Gendered opportunities to enhance direct‐to‐consumer advertising of gender‐neutral pharmaceutical brands: factors arising from information processing, message content, and demographic change. Business Review 2007;7(1):33‐9.
Harrabin R, Coote A, Allen J. Health in the News: Risk, Reporting and Media Influence. London (UK): King’s Fund Publications, 2003.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Chichester: John Wiley & Sons.
Hogue M‐CB, Doran E, Henry DA. A prompt to the web: the media and health information seeking behaviour. PLoS ONE 2012;7(4):1‐6. [DOI: 10.1371/journal.pone.0034314]
Leonardo Alves T, Mintzes B. A regulatory no man’s land: unbranded advertising of prescription drugs to the public in Europe. Poster presented at the Geneva Health Forum2007.
Leonardo Alves T, Martins de Freitas A, van Eijk MEC, Mantel‐Teeuwisse A. Compliance of disease awareness campaigns in printed Dutch media with national and international regulatory guidelines. PLoS One 2014;9(9):e106599. [DOI: 10.1371/journal.pone.0106599]
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100]
Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
Mansfield P, Mintzes B, Richards D, Toop L. Direct to consumer advertising. BMJ 2005;330(7481):5‐6. [DOI: http://dx.doi.org/10.1136/bmj.330.7481.5]
Mintzes B. Blurring the Boundaries: New Trends in Drug Promotion. Amsterdam: Health Action International Europe, 1998.
Mintzes B. "Ask your doctor" women and direct‐to‐consumer advertising. In: Rochon Ford A, Saibil D editor(s). The Push to Prescribe Women and Canadian Drug Policy. Toronto (CA): Women's Press, 2010.
Mintzes B. Advertising of prescription‐only medicines to the public: does evidence of benefit counterbalance harm?. Annual Review of Public Health 2012;33:259‐77.
Mosdøl A, Lidal IB, Straumann GH, Vist GE. Targeted mass media interventions promoting healthy behaviours to reduce risk of non‐communicable diseases in adult, ethnic minorities. Cochrane Database of Systematic Reviews 2015, Issue 5. [DOI: 10.1002/14651858.CD011683]
Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time series design in health technology assessment: lessons from two systematic reviews of behavior change strategies. International Journal of Technology Assessment in Health Care 2003;19(4):612.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen (DK): Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sterne JAC, Higgins JPT, Reeves BC, Savović J, Turner L, et al. ROBINS‐I. A tool for assessing risk of bias in non‐randomized studies of interventions. Version 7. Cochrane Bias Methods and Cochrane Non‐Randomised Studies Groups, 2016.
Schwartz LM, Woloshin S. Low “T” as in “Template”: how to sell disease: comment on “Promoting ‘Low T’”. JAMA Internal Medicine 2013;173(15):1460‐2. [DOI: 10.1001/jamainternmed.2013.7579]
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Annals of Internal Medicine 2006;145(4):284‐93.
Tiner R. The industry works to develop drugs, not diseases. BMJ 2002;325(7357):216.
Van Nuland S, Damen Z. Public information as a marketing tool. Promotion of diseases and medicines [Publieksvoorlichting als marketinginstrument. Promotie van ziekten en geneesmiddelen]. Gezonde Scepsis (Healthy Scepticism). Available from: apps.who.int/medicinedocs/documents/s17531en/s17531en.pdf. Utrecht, 2010.
Vitry A, Mintzes B. Disease mongering and low testosterone in men: the tale of two regulatory failures. Medical Journal of Australia 2012;196(10):619‐21.
Wielondek M. Can direct‐to‐consumer advertising help in reinventing the image of the pharmaceutical industry instead of eroding its credibility?. Journal of Medical Marketing 2005;5:264‐73.
| Key term | Definition |
| Branded direct‐to‐consumer advertising of prescription medicines (DTCA) | Advertising that includes a product's brand name. In the USA, this includes two types of advertising described by the Food and Drug Administration: 1) 'full product advertising', which includes the product name and health claims. Such advertising must also include information on the drug risks; 2) reminder advertising, which states the product's name but makes no health claims. In the USA, this advertising is not allowed for drugs with boxed warnings of serious risks. |
| Unbranded advertising of prescription medicines | Any paid advertising campaign, in any media, by a pharmaceutical manufacturer, with a focus on a condition treated by one or more of its products, but without any mention of brand or generic names. |
| Off‐label promotion | The term 'off‐label promotion' refers to promotion of a medicine for an unapproved use. This type of promotion is generally illegal. Physicians may prescribe a medicine for any use, whether it is approved or not, but manufacturers may not promote medicines for off‐label use. |
| Mixed promotion (both on‐ and off‐label) | 'On‐label promotion' refers to promotion for approved uses. 'Off‐label promotion' is for unapproved uses. Mixed promotion is for both types of uses. |
| Generic drugs or generics | Generic drugs or generics are medicines that have no brand name or registered trademark. Once the patent for a medicine expires, other manufacturers may produce the medicine, and these products are generic drugs. |
| Direct‐to‐consumer advertising | Direct‐to‐consumer advertising (DTCA) refers to advertising of prescription‐only medicines aimed at the public. Such advertising is fully legal only in two countries, the USA and New Zealand. |
| Non‐commercial information sources | We define a non‐commercial information source to be any public or private entity, institution, non‐government organisation, foundation or society involved in distributing information about health and treatment which does not derive a commercial gain from inducing the prescription, supply, purchase and/or use of pharmaceutical products, either directly or indirectly. |
| Third party acting on behalf of pharmaceutical company | Any public relations consultancy, marketing company, professional society, think tank, patient and consumer group, key opinion leader, medical practice or hospital, which has been hired or funded by a pharmaceutical company to promote specific pharmaceutical products. |
Figuras y tablas -
Table 1. Glossary of key terms
